Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News CASI Pharmaceuticals Inc CASI

Healthcare Biotechnology
CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing, and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. Its... see more

Recent & Breaking News (NDAQ:CASI)

Data Presented For ENMD-2076 In Xenograft Models Of Human Hepatocellular Carcinoma

PR Newswire October 22, 2013

Data Presented For ENMD-2076 In Preclinical Models Of Triple-Negative Breast Cancer

PR Newswire October 21, 2013

EntreMed Reports Second Quarter 2013 Financial Results

PR Newswire August 14, 2013

EntreMed Initiates Crossover Bioavailability And Food Effect Study Of ENMD-2076 Dosage Form To Be Used For Pivotal/Registration Clinical Trials

PR Newswire July 29, 2013

EntreMed Files New Drug Global Clinical Trial Application For ENMD-2076 With China CFDA To Expand Clinical Trial For Advanced/Metastatic Sarcoma

PR Newswire June 27, 2013

EntreMed Reports First Quarter 2013 Financial Results

PR Newswire May 15, 2013

Patent Issued In China For EntreMed's Lead Drug Candidate ENMD-2076

PR Newswire May 6, 2013

Patent Issued In U.S. For EntreMed's 2ME2 In Rheumatoid Diseases

PR Newswire May 3, 2013

EntreMed Announces Changes to Board of Directors and CEO Appointment

PR Newswire April 5, 2013

EntreMed Reports Fourth Quarter And Year-End 2012 Financial Results And Business Outlook For 2013

PR Newswire March 21, 2013

InvestorsGuru.com Filtered Mid-Day Market Movers Recap

Vivian Danielson March 3, 2013

Burrill Securities Acts as Exclusive Placement Agent for EntreMed $10.7 Million Registered Direct

Marketwired March 1, 2013

EntreMed To Raise $10.7 Million In Registered Direct Offering

PR Newswire March 1, 2013

Sharp Increase in FDA Drug Approvals a Major Factor in Biotech Industry's Success

Marketwired February 26, 2013

Perfect Trade Setups, How to Play ACRX, ENMD, NLY and WPI

Marketwired January 23, 2013

EntreMed Files New Drug Clinical Trial Application For ENMD-2076 With China SFDA To Advance Global Development Strategy

PR Newswire January 7, 2013

EntreMed Announces Initiation Of Second Site For Phase 2 Trial In Triple-Negative Breast Cancer

PR Newswire January 4, 2013

The Real Story Behind ENMD, SPMD, TIGR and TGS

Marketwired December 27, 2012